VYNE Annual CFO
-$25.34 M
+$3.86 M+13.22%
31 December 2023
Summary:
As of January 23, 2025, VYNE annual cash flow from operations is -$25.34 million, with the most recent change of +$3.86 million (+13.22%) on December 31, 2023. During the last 3 years, it has risen by +$111.74 million (+81.51%). VYNE annual CFO is now -1018.81% below its all-time high of -$2.27 million, reached on December 31, 2016.VYNE Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
VYNE Quarterly CFO
-$8.51 M
-$29.00 K-0.34%
30 September 2024
Summary:
As of January 23, 2025, VYNE quarterly cash flow from operations is -$8.51 million, with the most recent change of -$29.00 thousand (-0.34%) on September 30, 2024. Over the past year, it has dropped by -$29.00 thousand (-0.34%). VYNE quarterly CFO is now -23100.00% below its all-time high of $37.00 thousand, reached on June 30, 2017.VYNE Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
VYNE TTM CFO
-$30.11 M
-$3.36 M-12.55%
30 September 2024
Summary:
As of January 23, 2025, VYNE TTM cash flow from operations is -$30.11 million, with the most recent change of -$3.36 million (-12.55%) on September 30, 2024. Over the past year, it has dropped by -$3.36 million (-12.55%). VYNE TTM CFO is now -442.82% below its all-time high of -$5.55 million, reached on June 30, 2017.VYNE TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
VYNE Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +13.2% | -0.3% | -12.6% |
| 3 y3 years | +81.5% | -76.9% | -3.1% |
| 5 y5 years | +51.9% | -76.9% | -3.1% |
VYNE Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +55.0% | -76.9% | +15.1% | -20.4% | +46.6% |
| 5 y | 5-year | at high | +81.5% | -76.9% | +83.7% | -20.4% | +78.0% |
| alltime | all time | -1018.8% | +81.5% | <-9999.0% | +83.7% | -442.8% | +78.0% |
VYNE Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$8.51 M(+0.3%) | -$30.11 M(+12.6%) |
| June 2024 | - | -$8.48 M(+6.3%) | -$26.75 M(-3.9%) |
| Mar 2024 | - | -$7.98 M(+55.4%) | -$27.84 M(+9.9%) |
| Dec 2023 | -$25.34 M(-13.2%) | -$5.14 M(-0.3%) | -$25.34 M(+1.3%) |
| Sept 2023 | - | -$5.15 M(-46.2%) | -$25.02 M(-7.3%) |
| June 2023 | - | -$9.57 M(+74.8%) | -$26.99 M(+5.3%) |
| Mar 2023 | - | -$5.48 M(+13.9%) | -$25.64 M(-12.2%) |
| Dec 2022 | -$29.20 M(-48.2%) | -$4.81 M(-32.5%) | -$29.20 M(-15.1%) |
| Sept 2022 | - | -$7.13 M(-13.4%) | -$34.41 M(-23.2%) |
| June 2022 | - | -$8.22 M(-9.0%) | -$44.82 M(-15.2%) |
| Mar 2022 | - | -$9.04 M(-9.8%) | -$52.85 M(-6.2%) |
| Dec 2021 | -$56.37 M(-58.9%) | -$10.02 M(-42.9%) | -$56.37 M(-21.4%) |
| Sept 2021 | - | -$17.54 M(+7.9%) | -$71.72 M(-7.8%) |
| June 2021 | - | -$16.26 M(+29.5%) | -$77.82 M(-20.1%) |
| Mar 2021 | - | -$12.55 M(-50.5%) | -$97.42 M(-28.9%) |
| Dec 2020 | -$137.08 M | -$25.38 M(+7.4%) | -$137.08 M(+7.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2020 | - | -$23.64 M(-34.1%) | -$128.12 M(+6.0%) |
| June 2020 | - | -$35.86 M(-31.3%) | -$120.86 M(+21.8%) |
| Mar 2020 | - | -$52.21 M(+218.1%) | -$99.25 M(+52.5%) |
| Dec 2019 | -$65.10 M(+23.5%) | -$16.41 M(+0.2%) | -$65.10 M(-0.3%) |
| Sept 2019 | - | -$16.38 M(+15.0%) | -$65.30 M(+6.9%) |
| June 2019 | - | -$14.25 M(-21.1%) | -$61.10 M(+2.5%) |
| Mar 2019 | - | -$18.06 M(+8.7%) | -$59.59 M(+13.0%) |
| Dec 2018 | -$52.73 M(+86.9%) | -$16.62 M(+36.5%) | -$52.73 M(+14.0%) |
| Sept 2018 | - | -$12.17 M(-4.5%) | -$46.27 M(-0.7%) |
| June 2018 | - | -$12.74 M(+13.7%) | -$46.62 M(+37.8%) |
| Mar 2018 | - | -$11.20 M(+10.3%) | -$33.84 M(+19.9%) |
| Dec 2017 | -$28.22 M(+1146.0%) | -$10.16 M(-18.9%) | -$28.22 M(+56.2%) |
| Sept 2017 | - | -$12.52 M(<-9900.0%) | -$18.07 M(+225.7%) |
| June 2017 | - | $37.00 K(-100.7%) | -$5.55 M(-0.7%) |
| Mar 2017 | - | -$5.58 M | -$5.58 M |
| Dec 2016 | -$2.27 M(-45.9%) | - | - |
| Dec 2015 | -$4.18 M | - | - |
FAQ
- What is VYNE Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for VYNE Therapeutics?
- What is VYNE Therapeutics annual CFO year-on-year change?
- What is VYNE Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for VYNE Therapeutics?
- What is VYNE Therapeutics quarterly CFO year-on-year change?
- What is VYNE Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for VYNE Therapeutics?
- What is VYNE Therapeutics TTM CFO year-on-year change?
What is VYNE Therapeutics annual cash flow from operations?
The current annual CFO of VYNE is -$25.34 M
What is the all time high annual CFO for VYNE Therapeutics?
VYNE Therapeutics all-time high annual cash flow from operations is -$2.27 M
What is VYNE Therapeutics annual CFO year-on-year change?
Over the past year, VYNE annual cash flow from operations has changed by +$3.86 M (+13.22%)
What is VYNE Therapeutics quarterly cash flow from operations?
The current quarterly CFO of VYNE is -$8.51 M
What is the all time high quarterly CFO for VYNE Therapeutics?
VYNE Therapeutics all-time high quarterly cash flow from operations is $37.00 K
What is VYNE Therapeutics quarterly CFO year-on-year change?
Over the past year, VYNE quarterly cash flow from operations has changed by -$29.00 K (-0.34%)
What is VYNE Therapeutics TTM cash flow from operations?
The current TTM CFO of VYNE is -$30.11 M
What is the all time high TTM CFO for VYNE Therapeutics?
VYNE Therapeutics all-time high TTM cash flow from operations is -$5.55 M
What is VYNE Therapeutics TTM CFO year-on-year change?
Over the past year, VYNE TTM cash flow from operations has changed by -$3.36 M (-12.55%)